PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27435324-14 2016 CONCLUSION: The long-term treatment of PBC patients with fenofibrate as an adjunct to UDCA is safe and effective in improving ALP, but the treatment did not significantly reduce the estimated probability of liver-related death or need for liver transplantation. Fenofibrate 57-68 ATHS Homo sapiens 126-129 10634964-7 1999 CONCLUSIONS: Micronised fenofibrate therapy in patients with Type 2 diabetes improved an establisheded ALP resulting in a more favourable lipid and LDL subfraction profile. Fenofibrate 24-35 ATHS Homo sapiens 103-106 34697277-7 2021 Results: Among patients with aPBC treated with UDCA and fenofibrate, the ALP, GGT, and serum IgM levels decreased significantly (p<0.0001) over 48 weeks. Fenofibrate 56-67 ATHS Homo sapiens 73-76 32480421-4 2020 When fenofibrate was added to Ursodiol therapy there was a significant reduction and in some cases normalization of serum ALP, ALT, and AST abnormalities, as well as pro-inflammatory cytokines. Fenofibrate 5-16 ATHS Homo sapiens 122-125